AstraZeneca Pharma India Ltd. News and Updates

Keep track of all breaking news on AstraZeneca Pharma India Ltd. from all sources in a single place.

15 Apr 2025

8971.50

2.80%

AstraZeneca India surrenders marketing approval of prostate cancer drug

Business Standard

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

Number of FII/FPI investors increased from 147 to 164 in Mar 2025 qtr.

AstraZeneca Pharma India Ltd.

17 Mar 2025

8971.50

2.80%

AstraZeneca to buy EsoBiotec for up to $1 billion

Business Line

EsoBiotec's platform has the potential to transform cell therapy, according to AstraZeneca, by empowering the immune system to attack cancers

AstraZeneca Pharma India Ltd. is trading above all available SMAs

AstraZeneca Pharma India Ltd.

06 Mar 2025

8971.50

2.80%

AstraZeneca Pharma Gets CDSCO Nod To Import New Drug For Hyperkalaemia Treatment

NDTV Profit

The permission paves way for the launch of sodium zirconium cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma) in India.

AstraZeneca Pharma India Ltd. has gained 21.37% in the last 6 Months

AstraZeneca gets nod to import, sell hyperkalaemia treatment drug in India

Business Standard | 06 Mar 2025

AstraZeneca Pharma India Ltd.

03 Mar 2025

8971.50

2.80%

AstraZeneca Pharma India Gets CDSCO Approval To Sell Cancer Treatment Drug

NDTV Profit

The approval from CDSCO is for import, sale and distribution of Durvalumab solution.

AstraZeneca Pharma India Ltd. has gained 32.87% in the last 3 Months

AstraZeneca Pharma India gets CDSCO approval to import, sell cancer treatment medicine

Business Line | 03 Mar 2025

AstraZeneca Pharma India Ltd.

12 Feb 2025

8971.50

2.80%

to see Rapid results content

AstraZeneca Pharma India Ltd.

10 Feb 2025

8971.50

2.80%

AstraZeneca's cancer drug tops list of new brands launched in 2024

Business Standard

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs

AstraZeneca Pharma India Ltd. has gained 21.37% in the last 6 Months

AstraZeneca Pharma India Ltd.

10 Feb 2025

8971.50

2.80%

AstraZeneca Pharma India Gets Warning Letter From NSE

NDTV Profit

The warning letter was issued to AstraZeneca Pharma India for not complying with a regulatory norm that mandates the attendance of at least two independent directors in audit committee meeting.

Number of MF schemes increased from 40 to 53 in Mar 2025 qtr.

AstraZeneca Pharma India Ltd.

06 Feb 2025

8971.50

2.80%

AstraZeneca reports better than expected profit on higher cancer drug sales

Business Standard

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts surveyed by Bloomberg

Number of MF schemes increased from 40 to 53 in Mar 2025 qtr.

AstraZeneca Pharma India Ltd.

31 Jan 2025

8971.50

2.80%

AstraZeneca scraps $558 mn UK investment plans citing cut in govt support

Business Standard

The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain

AstraZeneca Pharma India Ltd. is trading above all available SMAs

AstraZeneca Pharma India Ltd.

17 Jan 2025

8971.50

2.80%

AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab

Business Standard

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO

Number of FII/FPI investors increased from 147 to 164 in Mar 2025 qtr.

AstraZeneca Pharma Gets Nod To Import New Drug Eculizumab

NDTV Profit | 16 Jan 2025

Is AstraZeneca Pharma India Ltd. worth buying?

146 Votes:

Buy 70.55%

Sell 19.86%

Hold 9.59%

New 52W High in past week

AstraZeneca Pharma India Ltd. News and Updates

Keep track of all breaking news on AstraZeneca Pharma India Ltd. from all sources in a single place.